Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
Journal of Gastroenterology|August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine|February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical PracticeHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective AnalysisTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter AnalysisTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Journal of Gastroenterology and Hepatology|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCCKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.
Hepatology (Baltimore, Md.)|May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyKaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.
Oncology|August 3, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus BevacizumabEmi Tanaka, Toshifumi Tada, Atsushi Hiraoka, et al.
Pageof 17